Among Patients in CCTG Phase III Cancer Trials Wednesday, October 02, 2019 The use of Complementary Medicines is Relatively High Among Patients in Phase III Cancer Trials Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by the Canadian Cancer Trials Group (CCTG) also used complementary medicines (CMs). The use of CMs was associated with improved survival in patients with lung cancer, although patient baseline characteristics were more favourable in these cohorts. These findings were recently presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. Lead author John C. Wells, Internal Medicine, Queen's University, Kingston, Canada noted that CMs are often used concurrently with conventional medical treatment by patients with cancer, but the extent of their use by patients in phase III studies and patient’s outcomes have not yet been determine More about the study: https://www.ctg.queensu.ca/cctg_news/palliative-and-supportive-care-presentation-esmo-2019
